Sugentech Inc. (KOSDAQ:253840)
7,070.00
-80.00 (-1.12%)
At close: Dec 5, 2025
Sugentech Revenue
Sugentech had revenue of 1.48B KRW in the quarter ending September 30, 2025, a decrease of -63.94%. This brings the company's revenue in the last twelve months to 9.01B, down -7.16% year-over-year. In the year 2024, Sugentech had annual revenue of 10.10B with 41.57% growth.
Revenue (ttm)
9.01B
Revenue Growth
-7.16%
P/S Ratio
12.00
Revenue / Employee
62.58M
Employees
144
Market Cap
108.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.10B | 2.96B | 41.57% |
| Dec 31, 2023 | 7.13B | -94.27B | -92.97% |
| Dec 31, 2022 | 101.40B | 24.20B | 31.34% |
| Dec 31, 2021 | 77.20B | 35.85B | 86.69% |
| Dec 31, 2020 | 41.35B | 37.51B | 975.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |